Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Tactile Systems Technology ( (TCMD) ) is now available.
On November 3, 2025, Tactile Systems Technology announced a new share repurchase program, authorizing the buyback of up to $25 million of its common stock by November 3, 2027. This initiative is expected to be funded through existing cash and future cash flows, reflecting the company’s confidence in its financial health and market position. The announcement coincided with the release of the company’s third-quarter financial results, which showed a 17% increase in total revenue to $85.8 million and a net income rise to $8.2 million. The company also highlighted the successful repayment of a $24 million term loan and an increase in its revolving credit facility capacity. These developments underscore Tactile Medical’s strategic focus on financial and operational growth, positioning it strongly for the remainder of 2025 and beyond.
The most recent analyst rating on (TCMD) stock is a Buy with a $23.50 price target. To see the full list of analyst forecasts on Tactile Systems Technology stock, see the TCMD Stock Forecast page.
Spark’s Take on TCMD Stock
According to Spark, TipRanks’ AI Analyst, TCMD is a Outperform.
Tactile Systems Technology scores well due to its strong financial performance and positive earnings call highlights, particularly in revenue growth and strategic execution. Technical indicators support a bullish outlook, while the valuation remains reasonable. The absence of corporate events and dividend yield slightly tempers the overall score.
To see Spark’s full report on TCMD stock, click here.
More about Tactile Systems Technology
Tactile Systems Technology, Inc., also known as Tactile Medical, is a medical technology company that specializes in developing and marketing at-home therapies for chronic conditions such as lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease. The company collaborates with clinicians to enhance clinical evidence, raise awareness, and improve access to care, aiming to reduce healthcare costs and improve the quality of life for patients.
Average Trading Volume: 202,098
Technical Sentiment Signal: Buy
Current Market Cap: $335.9M
For an in-depth examination of TCMD stock, go to TipRanks’ Overview page.